JP2016094451A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016094451A5 JP2016094451A5 JP2015246589A JP2015246589A JP2016094451A5 JP 2016094451 A5 JP2016094451 A5 JP 2016094451A5 JP 2015246589 A JP2015246589 A JP 2015246589A JP 2015246589 A JP2015246589 A JP 2015246589A JP 2016094451 A5 JP2016094451 A5 JP 2016094451A5
- Authority
- JP
- Japan
- Prior art keywords
- nmol
- hour
- composition
- naglu
- fold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 210000001519 tissue Anatomy 0.000 claims 9
- 230000002132 lysosomal effect Effects 0.000 claims 7
- 210000002569 neuron Anatomy 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000002093 peripheral effect Effects 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 210000000278 spinal cord Anatomy 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- 210000005013 brain tissue Anatomy 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000057877 human IGF2 Human genes 0.000 claims 2
- 210000004705 lumbosacral region Anatomy 0.000 claims 2
- 210000003712 lysosome Anatomy 0.000 claims 2
- 230000001868 lysosomic effect Effects 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 229960000502 poloxamer Drugs 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000012384 transportation and delivery Methods 0.000 claims 2
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000030979 Language Development disease Diseases 0.000 claims 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims 1
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010041467 Speech disorder developmental Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 claims 1
- 210000000576 arachnoid Anatomy 0.000 claims 1
- 210000001159 caudate nucleus Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000001638 cerebellum Anatomy 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 210000004884 grey matter Anatomy 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000002418 meninge Anatomy 0.000 claims 1
- 210000001259 mesencephalon Anatomy 0.000 claims 1
- 239000002052 molecular layer Substances 0.000 claims 1
- 210000000478 neocortex Anatomy 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 210000004786 perivascular cell Anatomy 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 229940044519 poloxamer 188 Drugs 0.000 claims 1
- 210000000449 purkinje cell Anatomy 0.000 claims 1
- 210000002637 putamen Anatomy 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000012385 systemic delivery Methods 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35885710P | 2010-06-25 | 2010-06-25 | |
| US61/358,857 | 2010-06-25 | ||
| US36078610P | 2010-07-01 | 2010-07-01 | |
| US61/360,786 | 2010-07-01 | ||
| US38786210P | 2010-09-29 | 2010-09-29 | |
| US61/387,862 | 2010-09-29 | ||
| US201161435710P | 2011-01-24 | 2011-01-24 | |
| US61/435,710 | 2011-01-24 | ||
| US201161442115P | 2011-02-11 | 2011-02-11 | |
| US61/442,115 | 2011-02-11 | ||
| US201161476210P | 2011-04-15 | 2011-04-15 | |
| US61/476,210 | 2011-04-15 | ||
| US201161495268P | 2011-06-09 | 2011-06-09 | |
| US61/495,268 | 2011-06-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516847A Division JP6063380B2 (ja) | 2010-06-25 | 2011-06-25 | サンフィリポ症候群ｂ型の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016094451A JP2016094451A (ja) | 2016-05-26 |
| JP2016094451A5 true JP2016094451A5 (cg-RX-API-DMAC7.html) | 2016-09-08 |
Family
ID=45352777
Family Applications (22)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236539A Active JP6250616B2 (ja) | 2010-06-25 | 2015-12-03 | 治療薬のｃｎｓ送達 |
| JP2015246258A Withdrawn JP2016040335A (ja) | 2010-06-25 | 2015-12-17 | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2015246244A Active JP6285409B2 (ja) | 2010-06-25 | 2015-12-17 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2015246589A Pending JP2016094451A (ja) | 2010-06-25 | 2015-12-17 | サンフィリポ症候群ｂ型の処置 |
| JP2015246952A Active JP6346162B2 (ja) | 2010-06-25 | 2015-12-18 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2017177784A Active JP6466538B2 (ja) | 2010-06-25 | 2017-09-15 | 治療薬のｃｎｓ送達 |
| JP2017194508A Active JP6522073B2 (ja) | 2010-06-25 | 2017-10-04 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2017194348A Active JP6522072B2 (ja) | 2010-06-25 | 2017-10-04 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2018192589A Active JP6797876B2 (ja) | 2010-06-25 | 2018-10-11 | 治療薬のｃｎｓ送達 |
| JP2018226358A Active JP6898909B2 (ja) | 2010-06-25 | 2018-12-03 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2018227369A Active JP6938456B2 (ja) | 2010-06-25 | 2018-12-04 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2020000930A Withdrawn JP2020079244A (ja) | 2010-06-25 | 2020-01-07 | 治療薬のｃｎｓ送達 |
| JP2020023620A Pending JP2020079297A (ja) | 2010-06-25 | 2020-02-14 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2020024183A Pending JP2020079298A (ja) | 2010-06-25 | 2020-02-17 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2021115564A Active JP7087175B2 (ja) | 2010-06-25 | 2021-07-13 | 治療薬のｃｎｓ送達 |
| JP2021115560A Active JP7448507B2 (ja) | 2010-06-25 | 2021-07-13 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2021133184A Active JP7591476B2 (ja) | 2010-06-25 | 2021-08-18 | イズロン酸－２－スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2021196898A Active JP7359827B2 (ja) | 2010-06-25 | 2021-12-03 | 治療薬のｃｎｓ送達 |
| JP2023014814A Active JP7543459B2 (ja) | 2010-06-25 | 2023-02-02 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2023024170A Pending JP2023062114A (ja) | 2010-06-25 | 2023-02-20 | イズロン酸－２－スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2023078673A Pending JP2023099216A (ja) | 2010-06-25 | 2023-05-11 | 治療薬のｃｎｓ送達 |
| JP2024069806A Ceased JP2024097029A (ja) | 2010-06-25 | 2024-04-23 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236539A Active JP6250616B2 (ja) | 2010-06-25 | 2015-12-03 | 治療薬のｃｎｓ送達 |
| JP2015246258A Withdrawn JP2016040335A (ja) | 2010-06-25 | 2015-12-17 | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2015246244A Active JP6285409B2 (ja) | 2010-06-25 | 2015-12-17 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
Family Applications After (18)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015246952A Active JP6346162B2 (ja) | 2010-06-25 | 2015-12-18 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2017177784A Active JP6466538B2 (ja) | 2010-06-25 | 2017-09-15 | 治療薬のｃｎｓ送達 |
| JP2017194508A Active JP6522073B2 (ja) | 2010-06-25 | 2017-10-04 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2017194348A Active JP6522072B2 (ja) | 2010-06-25 | 2017-10-04 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2018192589A Active JP6797876B2 (ja) | 2010-06-25 | 2018-10-11 | 治療薬のｃｎｓ送達 |
| JP2018226358A Active JP6898909B2 (ja) | 2010-06-25 | 2018-12-03 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2018227369A Active JP6938456B2 (ja) | 2010-06-25 | 2018-12-04 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2020000930A Withdrawn JP2020079244A (ja) | 2010-06-25 | 2020-01-07 | 治療薬のｃｎｓ送達 |
| JP2020023620A Pending JP2020079297A (ja) | 2010-06-25 | 2020-02-14 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2020024183A Pending JP2020079298A (ja) | 2010-06-25 | 2020-02-17 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2021115564A Active JP7087175B2 (ja) | 2010-06-25 | 2021-07-13 | 治療薬のｃｎｓ送達 |
| JP2021115560A Active JP7448507B2 (ja) | 2010-06-25 | 2021-07-13 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2021133184A Active JP7591476B2 (ja) | 2010-06-25 | 2021-08-18 | イズロン酸－２－スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2021196898A Active JP7359827B2 (ja) | 2010-06-25 | 2021-12-03 | 治療薬のｃｎｓ送達 |
| JP2023014814A Active JP7543459B2 (ja) | 2010-06-25 | 2023-02-02 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2023024170A Pending JP2023062114A (ja) | 2010-06-25 | 2023-02-20 | イズロン酸－２－スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2023078673A Pending JP2023099216A (ja) | 2010-06-25 | 2023-05-11 | 治療薬のｃｎｓ送達 |
| JP2024069806A Ceased JP2024097029A (ja) | 2010-06-25 | 2024-04-23 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
Country Status (24)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
| WO2009018122A2 (en) | 2007-07-27 | 2009-02-05 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-iduronidase activity in the cns |
| EP2485761B1 (en) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| US20220133863A1 (en) * | 2010-06-25 | 2022-05-05 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
| US9320711B2 (en) | 2010-06-25 | 2016-04-26 | Shire Human Genetic Therapies, Inc. | Methods and compositions for CNS delivery of heparan N-sulfatase |
| CN103282046B (zh) | 2010-06-25 | 2015-05-13 | 夏尔人类遗传性治疗公司 | 芳基硫酸酯酶 a cns 递送的方法和组合物 |
| WO2011163648A1 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| UA129740C2 (uk) | 2010-06-25 | 2025-07-23 | Такеда Фармасьютікал Компані Лімітед | Застосування композиції, що включає білок арилсульфатази а (аса) |
| CA2857647C (en) | 2011-12-02 | 2022-04-19 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
| WO2013096912A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
| WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| EP3622821A1 (en) * | 2013-05-15 | 2020-03-18 | Regents of the University of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| US10967073B2 (en) | 2015-05-07 | 2021-04-06 | The Mclean Hospital Corporation | Glucocerebrosidase gene therapy for Parkinson's disease |
| ES2978197T3 (es) | 2015-12-30 | 2024-09-06 | Green Cross Corp | Composiciones para usar en el tratamiento del síndrome de Hunter |
| BR112018017322A2 (pt) * | 2016-02-24 | 2019-01-02 | Biomarin Pharm Inc | proteínas de fusão de enzima lisossômica terapêuticas direcionadas, formulações associadas e usos das mesmas |
| MA44874A (fr) | 2016-04-15 | 2019-03-13 | Univ Pennsylvania | Thérapie génique pour traiter la mucopolysaccharidose de type ii |
| IL273427B2 (en) | 2017-09-22 | 2025-04-01 | Univ Pennsylvania | Gene therapy for the treatment of mucocutaneous polycythemia vera type II |
| CN119607188A (zh) * | 2018-02-28 | 2025-03-14 | 生化学工业株式会社 | 包装体及其制造方法 |
| CN108534695A (zh) * | 2018-05-04 | 2018-09-14 | 无锡恩特卫自动化检测设备有限公司 | 一种基于机器视觉系统的瓶塞漏酒检测方法及装置 |
| KR102671857B1 (ko) * | 2018-05-30 | 2024-06-04 | 주식회사 녹십자 | 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물 |
| EP3811962A4 (en) | 2018-06-25 | 2022-03-16 | JCR Pharmaceuticals Co., Ltd. | Protein-containing aqueous liquid formulation |
| JP7253770B2 (ja) * | 2019-01-18 | 2023-04-07 | 株式会社大一商会 | 遊技機 |
| JP7253771B2 (ja) * | 2019-01-18 | 2023-04-07 | 株式会社大一商会 | 遊技機 |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| CN113283465B (zh) * | 2021-04-02 | 2022-04-29 | 电子科技大学 | 一种弥散张量成像数据分析方法及装置 |
| WO2022271466A1 (en) | 2021-06-21 | 2022-12-29 | Juvena Therapeutics, Inc. | Regenerative polypeptides and uses thereof |
| CN115116623A (zh) * | 2022-06-28 | 2022-09-27 | 深圳市儿童医院 | 一种基于icd疾病编码的抗菌药物使用指标评价方法、终端 |
| WO2025054521A1 (en) * | 2023-09-07 | 2025-03-13 | Juvena Therapeutics, Inc. | Igf2 fusion protein formulations and therapeutic uses thereof |
| WO2025075929A1 (en) * | 2023-10-02 | 2025-04-10 | Neurona Therapeutics Inc. | Methods of treating seizure activity |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133001A (en) * | 1959-11-26 | 1964-05-12 | Muset Pedro Puig | Stabilization of enzymes |
| US4743265A (en) | 1986-04-23 | 1988-05-10 | Dij Catheter Corp | Articulated catheter placement device |
| US5222982A (en) | 1991-02-11 | 1993-06-29 | Ommaya Ayub K | Spinal fluid driven artificial organ |
| EP0682524B1 (en) * | 1993-02-02 | 2001-10-04 | XOMA Technology Ltd. | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
| US5863782A (en) | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| AUPN674895A0 (en) | 1995-11-23 | 1995-12-14 | Women's And Children's Hospital | Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same |
| DE69808402T2 (de) | 1997-08-22 | 2003-07-03 | Seikagaku Corp., Tokio/Tokyo | Arzneimittel zur Behandlung von durch Hernie gestörter intervertebraler Bandscheibe |
| EP2020438B1 (en) | 1998-12-07 | 2018-04-11 | Genzyme Corporation | Treatment of pompe's disease |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| US6368315B1 (en) | 1999-06-23 | 2002-04-09 | Durect Corporation | Composite drug delivery catheter |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
| US20020099025A1 (en) * | 1999-12-30 | 2002-07-25 | Heywood James A. | Treatment of neurological disorders |
| US6866844B2 (en) * | 2002-11-07 | 2005-03-15 | Biomarin Pharmaceutical Inc. | Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
| DE60224816T2 (de) | 2001-04-30 | 2009-01-22 | ZyStor Therapeutics, Inc., Milwaukee | Subzelluläres targeting von therapeutischen proteinen |
| US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20030040479A1 (en) | 2001-07-02 | 2003-02-27 | Omeros Corporation | Rotational intrathecal analgesia method and device |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| WO2003032727A1 (en) | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| AU2003211009A1 (en) | 2002-02-11 | 2003-09-04 | Wake Forest University | Compositions and methods for treating pain using cyclooxygenase-1 inhibitors |
| EP1503788B1 (en) * | 2002-04-25 | 2011-06-29 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-galactosidase a deficiency |
| WO2004037341A2 (en) | 2002-05-07 | 2004-05-06 | Schroeppel Edward A | Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
| EP1514106A4 (en) | 2002-05-29 | 2007-05-09 | Zystor Therapeutics Inc | TARGETED THERAPEUTIC PROTEINS |
| EP1426069A1 (en) | 2002-12-02 | 2004-06-09 | Diana Evelyn Miller | Drug delivery system |
| ES2371913T3 (es) | 2003-01-22 | 2012-01-11 | Duke University | Constructos mejorados para expresar polipéptidos lisosomales. |
| ES2686775T3 (es) | 2003-01-31 | 2018-10-19 | Mount Sinai School Of Medicine Of New York University | Terapia de combinación para tratar trastornos de deficiencia de proteínas |
| US8026209B2 (en) | 2003-02-10 | 2011-09-27 | Bbb Holding B.V. | Methods and compositions for targeting agents into and across the blood-barrier and other endothelial cell microvascular barriers |
| CN1788017B (zh) * | 2003-02-10 | 2013-04-24 | to-BBB控股股份有限公司 | 炎症状态下在血脑屏障中差异表达的核酸 |
| EP1638605B1 (en) | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| WO2005073367A1 (en) | 2004-01-30 | 2005-08-11 | Zymenex A/S | Production and purification of recombinant arylsulfatase a |
| US20060029656A1 (en) | 2004-02-03 | 2006-02-09 | Biodelivery Sciences International, Inc. | Replacement enzyme cochleates |
| AU2005211775B2 (en) | 2004-02-06 | 2009-10-08 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
| AU2005212435B2 (en) | 2004-02-10 | 2010-09-09 | Biomarin Pharmaceutical Inc. | Acid alpha-glucosidase and fragments thereof |
| US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| UA11577U (en) | 2004-04-21 | 2006-01-16 | Academician A P Romodanov Inst | Device for intrathecal drug administration into spinal canal |
| KR20070037444A (ko) * | 2004-06-15 | 2007-04-04 | 백스터 인터내셔널 인코포레이티드 | 고체 미립자성 치료제의 생체외 적용방법 |
| DE602005018226D1 (de) * | 2004-08-11 | 2010-01-21 | Basf Se | Zeit-temperatur-indikator auf enzymbasis |
| IL165334A0 (en) * | 2004-11-22 | 2006-01-15 | Mediwound Ltd | Debriding composition from bromelain and methods of producing same |
| WO2006121199A1 (ja) * | 2005-05-11 | 2006-11-16 | Oxygenix Co., Ltd. | 脂質小胞体組成物 |
| MX2007015602A (es) | 2005-06-08 | 2008-02-21 | Amicus Therapeutics Inc | Tratamiento de trastornos del sistema nervioso central asociados con mutaciones en genes que codifican las enzimas lisosomicas. |
| AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| PT1988823T (pt) * | 2006-02-09 | 2018-11-22 | Genzyme Corp | Administração intraventricular lenta |
| CN101410408A (zh) * | 2006-04-04 | 2009-04-15 | 希尔制药爱尔兰有限责任公司 | 用于浓缩多肽的方法 |
| NZ568728A (en) | 2006-04-04 | 2011-09-30 | Shire Pharmaceuticals Ireland Ltd | A process for concentration of a aryl sulfatase A |
| GB0611463D0 (en) | 2006-06-09 | 2006-07-19 | Novartis Ag | Organic compounds |
| US20080076120A1 (en) | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
| WO2008070769A1 (en) * | 2006-12-06 | 2008-06-12 | Medtronic, Inc. | Intrathecal catheter |
| WO2008109677A2 (en) | 2007-03-06 | 2008-09-12 | Saint Louis University | Modified enzyme and treatment method |
| EP2174661B1 (en) | 2007-06-29 | 2012-12-19 | National University Corporation Nagoya University | Agent for improving neuropathic pain |
| WO2009017005A1 (ja) | 2007-07-27 | 2009-02-05 | Sharp Kabushiki Kaisha | 移動局装置、基地局装置、通信システム及びプログラム |
| US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| US8470771B2 (en) * | 2007-11-14 | 2013-06-25 | Institute Of Microbiology, Chinese Academy Of Sciences | Method and medicament for inhibiting the infection of influenza virus |
| CN101969971A (zh) | 2007-11-30 | 2011-02-09 | 雅培制药有限公司 | 蛋白制剂及其制备方法 |
| US8128925B2 (en) | 2008-01-18 | 2012-03-06 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| US7722865B2 (en) * | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| TW200936156A (en) * | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| WO2009131698A2 (en) | 2008-04-23 | 2009-10-29 | Iowa State University Research Foundation, Inc. | PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF |
| US20110223147A1 (en) | 2008-05-07 | 2011-09-15 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| US8436489B2 (en) | 2009-06-29 | 2013-05-07 | Lightsail Energy, Inc. | Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange |
| WO2011163648A1 (en) * | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| CN103282046B (zh) | 2010-06-25 | 2015-05-13 | 夏尔人类遗传性治疗公司 | 芳基硫酸酯酶 a cns 递送的方法和组合物 |
| JP6063380B2 (ja) | 2010-06-25 | 2017-01-18 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | サンフィリポ症候群ｂ型の処置 |
| EP2588132A4 (en) | 2010-06-25 | 2014-10-15 | Shire Human Genetic Therapies | METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS |
| US9320711B2 (en) | 2010-06-25 | 2016-04-26 | Shire Human Genetic Therapies, Inc. | Methods and compositions for CNS delivery of heparan N-sulfatase |
| UA129740C2 (uk) | 2010-06-25 | 2025-07-23 | Такеда Фармасьютікал Компані Лімітед | Застосування композиції, що включає білок арилсульфатази а (аса) |
| SMT201900594T1 (it) * | 2010-06-25 | 2019-11-13 | Shire Human Genetic Therapies | Metodi e composizioni per il rilascio nell’snc di iduronato-2-solfatasi |
| JP2012062312A (ja) | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
| US8580922B2 (en) * | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| AU2015301809A1 (en) | 2014-08-11 | 2017-02-02 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
| EP3193942B1 (en) | 2014-08-11 | 2020-03-25 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting and uses thereof |
| EP3220958A1 (en) | 2014-10-24 | 2017-09-27 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting of enzymes, and uses thereof |
| US9673835B1 (en) | 2015-12-04 | 2017-06-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Pipelined SAR with TDC converter |
-
2011
- 2011-06-25 UA UAA201507721A patent/UA129740C2/uk unknown
- 2011-06-25 HU HUE11799035A patent/HUE031036T2/en unknown
- 2011-06-25 LT LTEP19192679.9T patent/LT3626258T/lt unknown
- 2011-06-25 HU HUE19192679A patent/HUE055963T2/hu unknown
- 2011-06-25 CN CN201510172262.0A patent/CN104857504A/zh active Pending
- 2011-06-25 CN CN201510512218.XA patent/CN105233277B/zh active Active
- 2011-06-25 HU HUE11799036A patent/HUE046856T2/hu unknown
- 2011-06-25 LT LTEP16179150.4T patent/LT3103469T/lt unknown
- 2011-06-25 PL PL11799035T patent/PL2588130T3/pl unknown
- 2011-06-25 DK DK19192679.9T patent/DK3626258T3/da active
- 2011-06-25 CA CA3171308A patent/CA3171308A1/en active Pending
- 2011-06-25 PE PE2018000183A patent/PE20180801A1/es unknown
- 2011-06-25 HU HUE11799037A patent/HUE046409T2/hu unknown
- 2011-06-25 SI SI201132014T patent/SI3626257T1/sl unknown
- 2011-06-25 MX MX2013000321A patent/MX354776B/es active IP Right Grant
- 2011-06-25 PT PT191925080T patent/PT3626257T/pt unknown
- 2011-06-25 BR BR112012033214-7A patent/BR112012033214B1/pt active IP Right Grant
- 2011-06-25 HU HUE19192508A patent/HUE056884T2/hu unknown
- 2011-06-25 NZ NZ702803A patent/NZ702803A/en unknown
- 2011-06-25 SI SI201131959T patent/SI3103469T1/sl unknown
- 2011-06-25 UA UAA201507529A patent/UA125743C2/uk unknown
- 2011-06-25 ES ES16179150T patent/ES2858726T3/es active Active
- 2011-06-25 PE PE2012002479A patent/PE20130637A1/es not_active Application Discontinuation
- 2011-06-25 PT PT117990358T patent/PT2588130T/pt unknown
- 2011-06-25 HU HUE16179150A patent/HUE052944T2/hu unknown
- 2011-06-25 CN CN201610086722.2A patent/CN105664142A/zh active Pending
- 2011-06-25 RS RS20211359A patent/RS62620B1/sr unknown
- 2011-06-25 HR HRP20211660TT patent/HRP20211660T1/hr unknown
- 2011-06-25 DK DK16179150.4T patent/DK3103469T3/da active
- 2011-06-25 PT PT191926799T patent/PT3626258T/pt unknown
- 2011-06-25 UA UAA201507719A patent/UA125060C2/uk unknown
- 2011-06-25 ES ES19192508T patent/ES2896060T3/es active Active
- 2011-06-25 SI SI201132007T patent/SI3626258T1/sl unknown
- 2011-06-25 HR HRP20211520TT patent/HRP20211520T1/hr unknown
- 2011-06-25 PE PE2012002498A patent/PE20130648A1/es not_active Application Discontinuation
- 2011-06-25 PE PE2012002476A patent/PE20130589A1/es not_active Application Discontinuation
- 2011-06-25 LT LTEP19192508.0T patent/LT3626257T/lt unknown
- 2011-06-25 RS RS20211191A patent/RS62520B1/sr unknown
- 2011-06-25 RU RU2017125281A patent/RU2761342C2/ru active
- 2011-06-25 PE PE2012002475A patent/PE20130579A1/es active IP Right Grant
- 2011-06-25 PT PT117990374T patent/PT2585104T/pt unknown
- 2011-06-25 ES ES19192679T patent/ES2895655T3/es active Active
- 2011-06-25 RS RS20210291A patent/RS61683B1/sr unknown
- 2011-06-25 PE PE2012002474A patent/PE20130578A1/es not_active Application Discontinuation
- 2011-06-25 CN CN201610569581.XA patent/CN106139133B/zh active Active
- 2011-06-25 DK DK19192508.0T patent/DK3626257T3/da active
- 2011-06-25 PE PE2017001612A patent/PE20180130A1/es unknown
- 2011-06-25 PE PE2017000503A patent/PE20170938A1/es unknown
- 2011-06-25 NZ NZ702800A patent/NZ702800A/en not_active IP Right Cessation
- 2011-06-25 PT PT117990366T patent/PT2593131T/pt unknown
- 2011-06-25 PT PT161791504T patent/PT3103469T/pt unknown
- 2011-06-27 TW TW112102995A patent/TWI876260B/zh active
- 2011-06-27 TW TW106135183A patent/TWI669128B/zh active
- 2011-06-27 TW TW113122692A patent/TW202506172A/zh unknown
- 2011-06-27 AR ARP110102241A patent/AR081677A1/es not_active Application Discontinuation
- 2011-06-27 AR ARP110102246A patent/AR082025A1/es not_active Application Discontinuation
- 2011-06-27 TW TW100122529A patent/TW201212936A/zh unknown
- 2011-06-27 TW TW106127273A patent/TWI698252B/zh active
- 2011-06-27 TW TW109118555A patent/TWI790444B/zh active
- 2011-06-27 AR ARP110102243A patent/AR081679A1/es unknown
- 2011-06-27 TW TW105115109A patent/TW201701899A/zh unknown
- 2011-06-27 TW TW100122534A patent/TWI602573B/zh active
- 2011-06-27 TW TW106108970A patent/TWI609694B/zh active
- 2011-06-27 AR ARP110102242A patent/AR081678A1/es not_active Application Discontinuation
- 2011-06-27 AR ARP110102244A patent/AR081680A1/es unknown
- 2011-06-27 AR ARP110102245A patent/AR081681A1/es unknown
-
2012
- 2012-12-21 CL CL2012003656A patent/CL2012003656A1/es unknown
- 2012-12-21 CL CL2012003654A patent/CL2012003654A1/es unknown
- 2012-12-21 CL CL2012003655A patent/CL2012003655A1/es unknown
- 2012-12-21 CL CL2012003657A patent/CL2012003657A1/es unknown
-
2013
- 2013-05-10 US US13/892,076 patent/US9814764B2/en active Active
- 2013-08-23 US US13/974,457 patent/US9220677B2/en active Active
-
2015
- 2015-11-11 US US14/938,824 patent/US20160158324A1/en not_active Abandoned
- 2015-12-03 JP JP2015236539A patent/JP6250616B2/ja active Active
- 2015-12-17 JP JP2015246258A patent/JP2016040335A/ja not_active Withdrawn
- 2015-12-17 JP JP2015246244A patent/JP6285409B2/ja active Active
- 2015-12-17 JP JP2015246589A patent/JP2016094451A/ja active Pending
- 2015-12-18 JP JP2015246952A patent/JP6346162B2/ja active Active
-
2016
- 2016-02-04 US US15/016,141 patent/US10456454B2/en active Active
- 2016-02-25 HK HK16102145.2A patent/HK1214149A1/zh unknown
- 2016-03-22 US US15/077,046 patent/US20170042977A1/en not_active Abandoned
- 2016-10-27 SM SM201600385T patent/SMT201600385B/it unknown
- 2016-12-07 CL CL2016003159A patent/CL2016003159A1/es unknown
-
2017
- 2017-08-23 US US15/684,568 patent/US10646554B2/en active Active
- 2017-09-15 JP JP2017177784A patent/JP6466538B2/ja active Active
- 2017-09-26 US US15/715,748 patent/US11065307B2/en active Active
- 2017-10-03 CL CL2017002488A patent/CL2017002488A1/es unknown
- 2017-10-04 JP JP2017194508A patent/JP6522073B2/ja active Active
- 2017-10-04 JP JP2017194348A patent/JP6522072B2/ja active Active
-
2018
- 2018-07-16 US US16/036,584 patent/US11065308B2/en active Active
- 2018-10-11 JP JP2018192589A patent/JP6797876B2/ja active Active
- 2018-12-03 JP JP2018226358A patent/JP6898909B2/ja active Active
- 2018-12-04 JP JP2018227369A patent/JP6938456B2/ja active Active
-
2019
- 2019-07-18 US US16/515,568 patent/US11260112B2/en active Active
- 2019-09-17 US US16/573,557 patent/US11471516B2/en active Active
-
2020
- 2020-01-07 JP JP2020000930A patent/JP2020079244A/ja not_active Withdrawn
- 2020-02-14 JP JP2020023620A patent/JP2020079297A/ja active Pending
- 2020-02-17 JP JP2020024183A patent/JP2020079298A/ja active Pending
- 2020-02-26 CL CL2020000468A patent/CL2020000468A1/es unknown
- 2020-03-24 US US16/828,731 patent/US12168041B2/en active Active
-
2021
- 2021-02-23 HR HRP20210298TT patent/HRP20210298T1/hr unknown
- 2021-06-17 US US17/350,860 patent/US12161702B2/en active Active
- 2021-07-13 JP JP2021115564A patent/JP7087175B2/ja active Active
- 2021-07-13 JP JP2021115560A patent/JP7448507B2/ja active Active
- 2021-08-18 JP JP2021133184A patent/JP7591476B2/ja active Active
- 2021-12-03 JP JP2021196898A patent/JP7359827B2/ja active Active
-
2022
- 2022-01-18 US US17/578,119 patent/US12121569B2/en active Active
- 2022-08-16 US US17/820,155 patent/US12409210B2/en active Active
-
2023
- 2023-02-02 JP JP2023014814A patent/JP7543459B2/ja active Active
- 2023-02-20 JP JP2023024170A patent/JP2023062114A/ja active Pending
- 2023-05-11 JP JP2023078673A patent/JP2023099216A/ja active Pending
-
2024
- 2024-04-23 JP JP2024069806A patent/JP2024097029A/ja not_active Ceased
- 2024-09-19 US US18/890,181 patent/US20250121040A1/en active Pending
- 2024-10-29 US US18/930,737 patent/US20250161417A1/en active Pending
-
2025
- 2025-08-15 US US19/301,198 patent/US20250375506A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016094451A5 (cg-RX-API-DMAC7.html) | ||
| JP2013542913A5 (cg-RX-API-DMAC7.html) | ||
| US10392605B2 (en) | P97-IDS fusion proteins | |
| JP2016040335A5 (cg-RX-API-DMAC7.html) | ||
| IL262976A (en) | Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof | |
| CN104039811B (zh) | 具有改善的细胞渗透性的新的大分子转导结构域的研发及其使用方法 | |
| WO2011157713A4 (en) | Cell-penetrating peptides and uses therof | |
| AU2018211985A1 (en) | Tissue-specific Wnt signal enhancing molecules and uses thereof | |
| JP2018522563A5 (cg-RX-API-DMAC7.html) | ||
| JP2010516290A5 (cg-RX-API-DMAC7.html) | ||
| WO2011036442A3 (en) | Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders | |
| JP2011504366A5 (cg-RX-API-DMAC7.html) | ||
| EA201200515A1 (ru) | Полипептиды и их применение | |
| US20170029798A1 (en) | Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD) | |
| JP2011528222A5 (cg-RX-API-DMAC7.html) | ||
| US12428445B2 (en) | Mini-nucleosome core proteins and use in nucleic acid delivery | |
| JP2025124629A (ja) | 治療用融合タンパク質 | |
| EP4286406A1 (en) | Fusion molecule having non-inflammatory phagocytosis inducing activity | |
| RU2016152151A (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда | |
| CN106279439A (zh) | 一种含有穿膜肽的寡肽‑1融合蛋白及其制备方法 | |
| JP2020037538A (ja) | アンジオテンシン変換酵素２活性を有する原核微生物由来ポリペプチドの医薬用途 | |
| WO2013052814A8 (en) | E1 enzyme mutants and uses thereof | |
| JP2019503171A5 (cg-RX-API-DMAC7.html) | ||
| US20150165013A1 (en) | Composition for use in mycobacteria vaccination | |
| CN119213021A (zh) | 与CD40L特异性结合的Stefin A蛋白变体及其用途 |